ALN-HSD + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Trial Timeline
Feb 9, 2023 → Sep 8, 2027
NCT ID
NCT05519475About ALN-HSD + Placebo
ALN-HSD + Placebo is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Metabolic Dysfunction-associated Steatohepatitis (MASH). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05519475. Target conditions include Metabolic Dysfunction-associated Steatohepatitis (MASH).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05519475 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metabolic Dysfunction-associated Steatohepatitis (MASH)